Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NI 1801

Next Previous
Drug Profile

NI 1801

Alternative Names: anti-CD47/MSLN antibodies - Light Chain Bioscience; Dual-targeting-mesothelin/CD47 bispecific antibodies - Light Chain Bioscience; NI-1801

Latest Information Update: 28 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Light Chain Bioscience
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; Macrophage stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Solid tumours

Most Recent Events

  • 28 May 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in France (Parenteral)
  • 28 Apr 2024 No recent reports of development identified for preclinical development in Solid-tumours in Switzerland (Parenteral)
  • 29 Jun 2022 Light Chain Bioscience submits clinical trial application to EU competent authorities for NI 1801 in Solid tumours before June 2022 (Light Chain Bioscience pipeline, June 2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top